NEW YORK (GenomeWeb) - Affymetrix reported after the close of the market Wednesday second quarter revenue growth of 4 percent, driven by increases in product revenues and in its genetic analysis business.

For the three months ended June 30, the company's revenues increased to $89 million from $85.4 million in the year-ago quarter. On a constant currency basis, its revenues increased almost 8 percent year over year, and beat the average Wall Street estimate of $88.6 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.